Application of solid lipid nanoparticles preparation in infection caused by antibiotic-resistant bacteria
Abstract
Solid lipid nanoparticles (SLN) is a potential alternative method for drug delivery due to its good stability, low toxicity, can be modified and controlled in drug release, as well as can be produced on a large scale. The SLNs are composed of solid lipids stabilized by emulsifiers. The lipids used for SLN are physiological lipids that easily tolerated by the body. These characteristics make SLN as a potential delivery system that can increase the efficiency of an antibiotics preparation. The development of bacterial resistance to antibacterial has become serious health problems in infectious diseases. Solid lipid nanoparticles is a compelling choice as a drug delivery system that can reduce the problem of the bacterial resistance. This review discussed the role of SLN as a drug carrier system which includes the characteristics and structure of SLN, its pharmacokinetic properties, bacterial resistance mechanism, and SLN mechanism in reducing bacterial resistance.
References
Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine 2016; 12(1):143-61.
https://doi.org/10.1016/j.nano.2015.09.004
Qushawy M, Nasr A. Solid Lipid Nanoparticles (SLNs) as nano drug delivery carriers: preparation, characterization, and application. Int J App Pharm 2020; 12(1):1-9
https://doi.org/10.22159/ijap.2020v12i1.35312
Ghasemiyeh P, Samani SM. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 2018; 13(4):288-303.
https://doi.org/10.4103/1735-5362.235156
Christaki E, Marcou M, Tofarides A. Antimicrobial resistance in bacteria: Mechanisms, evolution, and persistence. J Mol Evol 2020; 88(1):26-40.
https://doi.org/10.1007/s00239-019-09914-3
Arana L, Gallego L, Alkorta I. Incorporation of antibiotics into solid lipid nanoparticles: A promising approach to reduce antibiotic resistance emergence. Nanomaterials 2021; 11(1251):1-27
https://doi.org/10.3390/nano11051251
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 2015; 5(3):305–13.
https://doi.org/10.15171/apb.2015.043
Borges A, de Freitas V, Mateus N, Fernandes I, Oliveira J. Solid lipid nanoparticles as carriers of natural phenolic compounds. Antioxidants 2020; 9(10):998
https://doi.org/10.3390/antiox9100998
Nair A, Shah J, Al-Dhubiab B, Jacob S, Patel SS, Venugopala KN, et al. Clarithromycin solid lipid nanoparticles for topical ocular therapy: optimization, evaluation and in vivo studies. Pharmaceutics 2021; 13(4):523
https://doi.org/10.3390/pharmaceutics13040523
Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Advances 2020; 10:26777-91.
https://doi.org/10.1039/D0RA03491F
Balamurugan K & Chintamani P. Lipid nano particulate drug delivery: An overview of the emerging trend. Pharma Innov J 2018; 7(7):779-89
Razak SAA, Gazzali AM, Fisol FA, Abdulbaqi IM, Parumasivam T, Mohtar N, et.al. Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: An overview. Cancers 2021; 13(3):400.
https://doi.org/10.3390/cancers13030400
Alsaad A, Hussien A, Ghareeb M. Solid Lipid Nanoparticles (SLN) as a novel drug delivery system: a theoretical review. Sys Rev Pharm 2020; 11(5):259-73.
https://doi.org/10.31838/srp.2020.5.39
Gupta S, Kesarla R, Chotai N, Misra A, Omri A. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. BioMed Res Int 2017; 5984014.
https://doi.org/10.1155/2017/5984014
Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, et al. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics 2018; 10(4):191.
https://doi.org/10.3390/pharmaceutics10040191
Qi J, Lu Y, Wu W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab 2012 May 1;13(4):418-28.
https://doi.org/10.2174/138920012800166526
Zhang Z, Lu Y, Qi J, Wi W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B 2021; 11(8):2449-68.
https://doi.org/10.1016/j.apsb.2020.12.022
Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid Lipid Nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm 2015; 495(1):439-46.
https://doi.org/10.1016/j.ijpharm.2015.09.014
Hassan H, Bello R, Adam SK, Alias E, Affandi M¸ Shamsuddin AF, et al. Acyclovir-loaded solid lipid nanoparticles: optimization, characterization and evaluation of its pharmacokinetic profile. Nanomaterials 2020; 10(9):1785
https://doi.org/10.3390/nano10091785
Wang F, Cao J, Hao J, Liu K. Pharmacokinetics, tissue distribution and relative bioavailability of geniposide-solid lipid nanoparticles following oral administration. J Microencapsul 2014; 31(4):382-9.
https://doi.org/10.3109/02652048.2013.863396
Luo CF, Yuan M, Chen MS, Liu SM, Zhu L, Huang BY, et al. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 2011; 410(1-2):138-44
https://doi.org/10.1016/j.ijpharm.2011.02.064
Purvin S, Vuddanda PR, Singh SK, Jain A, Singh S. Pharmacokinetic and tissue distribution study of solid lipid nanoparticles of zidovudine in rats. J Nanotechnol 2014; 1-7.
https://doi.org/10.1155/2014/854018
Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol 2018; 4(3):482-501.
https://doi.org/10.3934/microbiol.2018.3.482
Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr 2016; 4(2):10.1128/microbiolspec.VMBF-0016-2015.
https://doi.org/10.1128/microbiolspec.VMBF-0016-2015
dos Santos RMA, de Toledo LG, Spósito L, Marena GD, de Lima LC, Fortunato GC, et al. Nanotechnology-based lipid systems applied to resistant bacterial control: A review of their use in the past two decades. Int J Pharm 2021; 603.
https://doi.org/10.1016/j.ijpharm.2021.120706
Vanamala K, Tatiparti K, Bhise K, Sau S, Scheetz MH, Rybak MJ, et al. Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discov Today 2021; 26(1):31-43.
https://doi.org/10.1016/j.drudis.2020.10.011
Muraca GS, Soler-Arango J, Castro GR, Islan GA, Brelles-Mariño G. Improving ciprofloxacin antimicrobial activity through lipid nanoencapsulation or non-thermal plasma on Pseudomonas aeruginosa biofilms. J Drug Deliv Sci Technol 2021; 64:102644.
https://doi.org/10.1016/j.jddst.2021.102644
Severino P, Silveira EF, Loureiro K, Chaud MV, Antonini D, Lancellotti M, et al. Antimicrobial activity of polymyxin-loaded solid lipid nanoparticles (PLX-SLN): Characterization of physicochemical properties and in vitro efficacy. Eur J Pharm Sci 2017; 106:177-84.
https://doi.org/10.1016/j.ejps.2017.05.063
Mullis AS, Peroutka-Bigus N, Phadke KS, Bellaire BH, Narasimhan B. Nanomedicines to counter microbial barriers and antimicrobial resistance. Curr Opin Chem Eng 2021; 31:100672.
https://doi.org/10.1016/j.coche.2021.100672
Malaekeh-Nikouei B, Fazly Bazzaz BS, Mirhadi E, Tajani AS, Khameneh B. The role of nanotechnology in combating biofilm-based antibiotic resistance. J Drug Deliv Sci Technol 2020; 60:101880.
https://doi.org/10.1016/j.jddst.2020.101880
Vairo C, Basas J, Pastor M, Palau M, Gomis X, Almirante B, et al. In vitro and in vivo antimicrobial activity of sodium colistimethate and amikacin-loaded nanostructured lipid carriers (NLC). Nanomedicine 2020; 29:102259.
https://doi: 10.1016/j.nano.2020.102259.
